| Prev Close | 102.44 |
| Open | 102.19 |
| Day Low/High | 102.19 / 105.62 |
| 52 Wk Low/High | 62.31 / 84.14 |
| Volume | 547.92K |
| Avg Volume | 346.60K |
| Exchange | NASDAQ |
| Shares Outstanding | 54.04M |
| Market Cap | 5.52B |
| EPS | 4.80 |
| P/E Ratio | 25.73 |
| Div & Yield | N.A. (N.A) |
Latest News
ICON Shareholders Vote In Favour Of All Resolutions At Its Annual General Meeting
ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General...
ICON Wins ELearning And Animation Awards For Its FIRECREST Digital Solutions
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that its FIRECREST solutions have won gold and...
ICON And DIA Amplify Thought Leadership And Debate With DIA Live 2017
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that for the second consecutive year it will present...
ICON Named By Forbes As One Of The Best Employers In America
ICON plc , (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been included in Forbes...
ICON Reports First Quarter 2017 Results
ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter...
Parexel Is Discovering the Drugs of the Future
The midcap drug maker is finding growth as an outsourcing destination.
ICON Selected By The FDA To Validate Patient-Reported Outcome Endpoints For Antibacterial Drug Trials
ICON plc , (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US...
ICON Reports Fourth Quarter And Full Year 2016 Results
ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the fourth quarter...
ICON Issues Financial Guidance For Full Year 2017
ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced its financial guidance for the year ended...
ICON Further Enhances Clinical Trial Feasibility, Protocol Optimisation And Patient Recruitment Capabilities With TriNetX
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has further improved its feasibility,...
ICON Announces Appointment Of Mr. Ronan Murphy To Board Of Directors
ICON plc , (NASDAQ:ICLR) global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Mr.
ICON Announces Executive Leadership Transition
ICON plc , (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that, as part of its planned succession of...
ICON Reports Third Quarter 2016 Results
ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third quarter...
ICON Completes The Acquisition Of Clinical Research Management, Inc.
ICON plc , (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the previously announced...
Icon (ICLR) Marked As A Barbarian At The Gate
Trade-Ideas LLC identified Icon (ICLR) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
ICON Reports Second Quarter 2016 Results
ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter...
ICON Shareholders Vote In Favour Of All Resolutions At Its Annual General Meeting
ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General...
ICON To Acquire Clinical Research Management, Inc.
ICON plc , (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain...
Healthcare Opportunities in Light of Brexit-Driven Selloff
The sharp declines seen across the healthcare sector could present buying opportunities in companies such as Aetna, HCA, Icon and Paraxel.
ICON: DIA Live To Provide A Digital Window Into DIA Conference 2016
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it will be presenting DIA Live - a social media...
New Research From ICON Demonstrates Support For 'Bring Your Own Device' Approach In Clinical Trials
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced research showing many pharmaceutical and clinical...
ICON Announces Service Agreement With Pfizer
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc.
ICON And Pfizer Honoured As Clinical Research Team Of The Year At The Clinical And Research Excellence Awards
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that, together with Pfizer, it has won the Clinical...
ICON Reports First Quarter 2016 Results
ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter...
Goldman Sachs Gives These 4 Cheap Stocks a Thumbs Up and So Do the Charts
Investors are on the hunt for cheap stocks. Here are four that are backed up by positive charts.
14 Cheap Stocks to Buy Now From Goldman Sachs
These 14 inexpensive stocks are expected to have strong top-line growth in the next two years, says Goldman Sachs.
Mr. Thomas Lynch Notifies ICON Of His Retirement As Chairman And That He Will Not Stand For Re-Election To The Board Of Directors At The Annual General Meeting
ICON plc , (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr.
ICON Selected By The International Consortium For Health Outcomes Measurement To Help Advance Value-based Healthcare
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by the International...
